trending Market Intelligence /marketintelligence/en/news-insights/trending/0_fob5z4o6imbmf00asqpq2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Cynata stem cell therapy gets US orphan drug status

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Cynata stem cell therapy gets US orphan drug status

The U.S. Food and Drug Administration granted orphan drug status to Cynata Therapeutics Ltd.'s stem cell therapy CYP-001.

The drug is meant to treat the acute graft versus host disease, which occurs after transplant procedures when immune cells from transplanted tissue attack the recipient. The disease has a high mortality rate.

The orphan drug status will help expedite development of CYP-001 and entitles Cynata to seven years of exclusive market rights and tax credits once the treatment is commercialized.

CYP-001 is being studied in an early stage trial.